Header: 80% of PLA codes were paid via MolDx. About 10% each for Novitas and NGS MAC, but the NGS MAC PLA payments were mostly NCD-driven payments for Foundation Medicine.
___
In the previous blog, I looked at payments for Genomic Miscellaneous Code, 81479, by MAC - here. I used the CMS cloud data archive for 2022 Part B payments - here.
In this blog, I pulled the CPT codes ending in "U" - the PLA codes - and sorted them in Excel for "Carrier" (usually a state), and sorted those into the three MACs for policies - the MolDx MACs, the NGS MACs, and the Novitas/FCSO MACs.
To save manual work, I deleted rows less than $100,000, leaving $330M of PLA payments (97% of the total). Of this $330M, about $18M were paid out to diverse MACs (such as for a Cepheid IVD, 0241U), which I didn't try to parse by MAC.
Of the $312M paid to specific MACs for PLA codes, I tallied $252M or 81% to MolDx MACs, and roughly $30M each to Novitas MACs and NGS MACs (about 9-10% each.)
Note, however, that much of the NGS MAC payments come from PLA codes 0037U and 0239U, Foundation Medicine FDA CDx codes (FFPE and LBX, respectively) - these are controlled by an NCD, NCD 90.2, and are not discretionary payments under the judgment of the NGS MAC. If you tallied NGS MAC payments NOT controlled by NCD 90.2, it would be very low.
Click to enlarge.
 |
| click to enlarge |
